Figure 4 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer

Le résumé fourni par la source

Short-term olaparib treatment does not cause major genomic changes. A, Growth curves displaying raw data of model 1006 treated with olaparib for 11 weeks (purple) or untreated controls (black). Dotted line indicates end of treatment, after which, tumors were left to progress until size limits. B, Correlation plots comparing mean VAFs of mutations between untreated and treated (left) or untreated and post-treated (right) samples. R value calculated using the Spearman correlation. C, Heatmap displaying VAFs of depleted and emergent mutations in each sample. Columns indicate samples (labeled by mouse number and intratumor region). OC, oncogenic classification as predicted by Cancer Genome Interpreter.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.